Drug Profile
Research programme: affective disorder therapies - Alte Bioscience
Alternative Names: ARX-111Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Duke University Medical Center
- Developer Alte Biosciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cerebral ischaemia; Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cerebral-ischaemia in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in USA
- 17 Oct 2007 Preclinical trials in Cerebral ischaemia in USA (unspecified route)